Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Andrea Giovanni Multari"'
1
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer
Autor: Pietro Rosellini, Giorgio Chiriacò, Giandomenico Roviello, Giovanni Paganini, Andrea Giovanni Multari, Roberto Petrioli, Michele Aieta, Raffaele Conca
Publikováno v: Investigational New Drugs. 37:524-530
Purpose Few data described the activity of chemotherapy after ramucirumab plus paclitaxel progression in metastatic gastric cancer patients. The aim of this phase II study is to assess the efficacy and safety of the FOLFIRI regimen as a third-line of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be117b6db84856dc72cda3f71f1ca51
https://doi.org/10.1007/s10637-019-00725-3
Zobrazit plný text záznamu
2
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study
Autor: Edoardo Francini, Virginia Livellara, Steven R. Alberts, Guido Francini, Guido Pesola, Eric G. Wolfe, Fang-Shu Ou, Joleen M. Hubbard, Elena Colombo, Sara Cherri, Roberto Petrioli, Luciana Messuti, Stefano Lazzi, Salvatora Tindara Miano, Harry H. Yoon, Andrea Giovanni Multari, Serena Bazzurri
Publikováno v: Translational Oncology
Translational Oncology, Vol 14, Iss 2, Pp 100973-(2021)
Highlights • Low CD3+ TILs rate was associated with shorter OS in those with stage II colon cancer who did not receive adjuvant therapy. • CD3+ TILs rate was not prognostic for patients with stage II colon cancer who had adjuvant therapy. • Low
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::086c6df88bf100ea58efd73d926f72a5
http://europepmc.org/articles/PMC7750416
Zobrazit plný text záznamu
3
Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer
Autor: Alberto D'Angelo, Pietro Rosellini, Michele Aieta, Giandomenico Roviello, Giorgio Chiriacò, Giovanni Paganini, Andrea Giovanni Multari, Silvia Paola Corona, Roberto Petrioli, Raffaele Conca
Publikováno v: Roviello, G, Conca, R, D'Angelo, A, Multari, A G, Paganini, G, Chiriacò, G, Petrioli, R, Corona, S P, Rosellini, P & Aieta, M 2020, ' Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer ', Anti-Cancer Drugs, vol. 31, no. 6, pp. 632-636 . https://doi.org/10.1097/CAD.0000000000000905
PURPOSE: The aim of this study was to evaluate if the occurrence of neutropenia is correlated with response to ramucirumab plus paclitaxel for metastatic gastric cancer.METHODS: This is a retrospective study of patients treated with ramucirumab plus
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bbd34c1922c33ed3b1bd23b818c1eee
https://pubmed.ncbi.nlm.nih.gov/32011363
Zobrazit plný text záznamu
4
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials
Autor: Daniele Generali, Chiara Pacifico, Giandomenico Roviello, Andrea Giovanni Multari, Angela Gobbi, Giulia Borsella, Laura Zanotti, Maria Rosa Cappelletti
Publikováno v: Critical Reviews in Oncology/Hematology. 108:62-68
Several new biological agents have been investigated as second line of treatment in advanced Hepatocellular Cancer (HCC). We performed a meta -analysis to assess the effect of targeted therapies in advanced HCC patients beyond the first line of treat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a16fa4d5d27c2647abf0a2d8dd067686
https://doi.org/10.1016/j.critrevonc.2016.10.015
Zobrazit plný text záznamu
5
Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel
Autor: Giandomenico Roviello, Andrea Giovanni Multari, Pietro Rosellini, Michele Aieta, Silvia Paola Corona, Roberto Petrioli
Publikováno v: Anti-cancer drugs. 30(7)
The aim of this report is to investigate the activity of ramucirumab in combination with paclitaxel in patients with metastatic gastric cancer (GC) and lung metastases. We retrospectively reviewed clinical data from patients with GC treated in second
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e886ce8100a5ec30142bc6c5c448df5
https://pubmed.ncbi.nlm.nih.gov/31305296
Zobrazit plný text záznamu
6
CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ)
Autor: Virginia Livellara, Andrea Giovanni Multari, Guido Francini, Stefano Lazzi, Luciana Messuti, Fang-Shu Ou, Edoardo Francini, Sara Cherri, Joleen M. Hubbard, Roberto Petrioli, Guido Pesola, Steven R. Alberts, Harry H. Yoon, Elena Colombo, Eric G. Wolfe, Serena Bazzurri, Miano Salvatora
Publikováno v: Journal of Clinical Oncology. 38:167-167
167 Background: Previous studies have reported high TILs are a favorable prognostic factor in stage II CC. However, whether the impact of TILs on overall survival (OS) differs among pts who did or did not receive ADJ is still to be determined. We ass
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69bd8be16a1dd1dbb45d28384057b7e3
https://doi.org/10.1200/jco.2020.38.4_suppl.167
Zobrazit plný text záznamu
7
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer
Autor: Giorgio Chiriacò, Giovanni Paganini, Roberto Petrioli, Pietro Rosellini, Giandomenico Roviello, Silvia Paola Corona, Daniele Generali, Andrea Giovanni Multari, Michele Aieta, Raffaele Conca
Publikováno v: Oncotarget
// Giandomenico Roviello 1 , Silvia Paola Corona 2 , Andrea Giovanni Multari 3 , Giovanni Paganini 4 , Giorgio Chiriaco 5 , Raffaele Conca 1 , Roberto Petrioli 6 , Daniele Generali 7, 8 , Pietro Rosellini 6 and Michele Aieta 1 1 Division of Medical O
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9d37e83ea43885181485653a6b4545e
http://hdl.handle.net/11368/2935422
Zobrazit plný text záznamu
8
Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis
Autor: Daniele Marrelli, Giandomenico Roviello, Karol Polom, Andrea Giovanni Multari, Chiara Pacifico, Daniele Generali, Giovanni Paganini, Franco Roviello
Publikováno v: Cancer investigation. 35(3)
Angiogenesis is a key process in cancer development. We performed a meta-analysis to assess the efficacy and safety of the novel VEGFR-2 inhibitors in patients with metastatic gastric and gastroesophageal junction cancer. A literature-based meta-anal
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eff8b83a9f9056a8b408591e7f1c8bf
https://pubmed.ncbi.nlm.nih.gov/28165839
Zobrazit plný text záznamu
9
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer
Autor: Giandomenico Roviello, Michele Aieta, Pietro Rosellini, Raffaele Conca, Valerio Nardone, Roberto Petrioli, Andrea Giovanni Multari
Publikováno v: Medicine. 97:e10745
The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ca6039b250bd3f802c660475064089
https://doi.org/10.1097/md.0000000000010745
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje